Cardiol Therapeutics Inc. focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD)Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study. The company is also developing a proprietary subcutaneous formulation of cannabidiol to achieve higher bioavailability.
